Group 1 - The company held its 9th temporary board meeting of the 11th session on November 12, 2025, with all 9 directors present [1][2][3] - The board approved the reappointment of Beijing Dehao International Accounting Firm as the auditor for the fiscal year 2025, which requires shareholder approval [5][6][8] - The board also approved a guarantee limit of RMB 160 million for its wholly-owned subsidiaries, with specific allocations for Harbin Shengtai Biological Pharmaceutical Co., Ltd. and Chengdu Yongkang Pharmaceutical Co., Ltd. [9][10][17] Group 2 - The company plans to hold its 4th temporary shareholders' meeting on November 28, 2025, to discuss the approved proposals from the board meeting [14][55] - The meeting will allow for both on-site and online voting, with specific timeframes for participation [56][70] - The company has ensured compliance with relevant laws and regulations for the meeting's organization [54][61] Group 3 - The total external guarantee balance after the new guarantees will be RMB 203.305 million, which represents 90.14% of the company's audited net assets for 2024 [26][36] - The guarantees are exclusively for wholly-owned subsidiaries, with no overdue guarantees or litigation related to the guarantees reported [26][36] - The board believes that the guarantees will enhance decision-making efficiency and support the subsidiaries' operational needs [24][34] Group 4 - The company has a strong credit rating and has not been subject to any significant legal or financial penalties [20][21][31] - The financial health of the subsidiaries, including their debt ratios, has been considered in the guarantee approvals [17][19] - The company aims to utilize its resources effectively to support its subsidiaries while managing associated risks [24][34]
通化金马药业集团股份有限公司 第十一届董事会2025年第九次临时会议决议公告